Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources

Rheumatology and Therapy

Volumn 3, Issue 2, 2016, Pages 337-352

  Monemi, Sharareh ^a   Berber, Erhan ^a   Sarsour, Khaled ^a   Wang, Jianmei ^b   Lampl, Kathy ^a   Bharucha, Kamal ^a   Pethoe Schramm, Attila ^c  

^a GENENTECH INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Gastrointestinal perforation; Rheumatoid arthritis; Tocilizumab

Indexed keywords

EID: 85034703112     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-016-0037-z     Document Type: Article

References (23)

1. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2007;66:1356–62. DOI: 10.1136/ard.2006.066662
2. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37. DOI: 10.1002/art.21519
3. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82. DOI: 10.1016/S0140-6736(08)61000-4
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509. DOI: 10.1136/annrheumdis-2013-204573
5. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97. DOI: 10.1016/S0140-6736(08)60453-5
6. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23. DOI: 10.1136/ard.2008.092932
7. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80. DOI: 10.1002/art.23940
8. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609–21. DOI: 10.1002/art.30158
9. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96. DOI: 10.1136/ard.2008.105197
10. Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:1653–61. DOI: 10.1002/acr.22384
11. Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:344–54. DOI: 10.1002/acr.22110
12. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73:69–74. DOI: 10.1136/annrheumdis-2013-203523
13. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081–91. DOI: 10.1136/annrheumdis-2015-207628
14. Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum. 2015;44:381–8. DOI: 10.1016/j.semarthrit.2014.07.006
15. Del Valle J. Peptic ulcer disease and related disorders. Harrison’s principles of internal medicine, 18 edn. New York: McGraw-Hill; 2012. p. Ch. 293.
16. Myasoedova E, Matteson EL, Talley NJ, Crowson CS. Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. J Rheumatol. 2012;39:1355–62. DOI: 10.3899/jrheum.111311
17. Curtis JR, Lanas A, John A, Johnson DA, Schulman KL. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:1819–28. DOI: 10.1002/acr.21764
18. Curtis JR, Xie F, Chen L, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum. 2011;63:346–51. DOI: 10.1002/art.30107
19. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74:694–702. DOI: 10.1136/annrheumdis-2013-204345
20. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–50. DOI: 10.1016/S0140-6736(13)60250-0
21. Curtis JR, Chen SY, Werther W, John A, Johnson DA. Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. Pharmacoepidemiol Drug Saf. 2011;20:1150–8. DOI: 10.1002/pds.2215
22. Xie F, Yun H, Bernatsky S, Curtis J. Risk for gastrointestinal perforation among rheumatoid arthritis patients recieving tofacitinib, tocilizumab, or other biologics. Arthritis Rheumatol. 2016. doi:10.1002/art39761 [Epub ahead of print]. DOI: 10.1002/art39761
23. Strangfeld A, Richter A, Herzer P, et al. Risk for lower perforations in RA patients treated with tocilizumab in comparison to treatment with TNF inhibitors, rituximab, abatacept or conventional synthetic DMARDs [oral presentation]. Arthritis Rheumatol. 2015;67(Suppl):S10.